Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 26

Results For "disease"

2057 News Found

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer
Drug Approval | November 19, 2024

Tagrisso recommended for approval in the EU for unresectable EGFR-mutated lung cancer

Recommendation based on LAURA Phase III trial results which showed Tagrisso extended median progression-free survival to more than three years


USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency
Drug Approval | November 16, 2024

USFDA approves first gene therapy for treatment of aromatic L-amino acid decarboxylase deficiency

Aromatic L-amino acid decarboxylase deficiency is a rare genetic disorder that affects the production of some neurotransmitters


Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024
News | November 14, 2024

Bristol Myers Squibb showcases cardiovascular portfolio at AHA Scientific Sessions 2024

Real-world and long-term extension data, including updated results from post-launch evaluation of REMS Program, bolster growing body of evidence supporting the efficacy and safety profile of CAMZYOS


AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr
News | November 14, 2024

AstraZeneca Pharma India posts Q2 PAT at Rs. 38.43 Cr

We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%


Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC
News | November 05, 2024

Lonza’s Synaffix collaborates with BigHat Biosciences for ML-designed ADC

Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies


AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics
News | November 05, 2024

AbbVie and EvolveImmune Therapeutics collaborate to develop next-generation cancer biotherapeutics

Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer


AbbVie to acquire Aliada Therapeutics
News | November 01, 2024

AbbVie to acquire Aliada Therapeutics

Strengthening focus in Alzheimer's disease and neuroscience pipeline


GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
News | November 01, 2024

GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline

CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus